|
WO2016161410A2
|
|
Treatment of cancer using inhibitors of tgf-beta and pd-1
|
|
AU2015200664A1
|
|
Methods and materials for targeted mutagenesis
|
|
CN103732623A
|
|
Antibodies specific for TGF-beta
|
|
CN103492562A
|
|
Methods and materials for enhancing functional protein expression in bacteria
|
|
WO2012092323A1
|
|
Cell surface display using pdz domains
|
|
AU2011205166A1
|
|
IL-1beta, binding antibodies and fragments thereof
|
|
CN102883748A
|
|
Methods for the treatment of IL-1beta related conditions
|
|
AU2013203214A1
|
|
Methods for the treatment of IL-1ß related conditions
|
|
WO2011038302A2
|
|
Insulin receptor binding antibodies
|
|
EP2473191A1
|
|
Antibody coformulations
|
|
WO2011028961A2
|
|
Anti-botulism antibody coformulations
|
|
WO2011009090A1
|
|
Antibodies to high molecular weight melanoma associated antigen
|
|
KR20110118628A
|
|
Flexible manufacturing system
|
|
WO2010080518A1
|
|
Methods and materials for determining isoelectric point
|
|
AU2009298192A1
|
|
Novel triple tag sequences and methods of use thereof
|
|
US2011118447A1
|
|
Methods and materials for targeted affinity enhancement
|
|
MX2010006823A
|
|
Methods for the treatment of gout.
|
|
MX2009006709A
|
|
Methods for the treatment of il-1ã¿ related diseases.
|
|
BRPI0720928A2
|
|
A method for treating a human being, a disease or condition, and using an anti-IL-1-BETA antibody or a fragrance thereof.
|
|
CN101616690A
|
|
The method that is used for the treatment of the IL-1 ss related diseases
|
